KO
$85.78
-1.94
(-2.21%)
As of Oct 22, 2026, 9:31 PM EDT · cached
Price history
Today's analyst average
Analyst average over timeIndividual analyst targets
Analyst history starts Sep 28, 2026, the first target we tracked for KOD.
Kodiak Sciences Inc (KOD) is trading down at $85.78 (-2.21%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
IPO: October 4, 2018 · $10.00 offering · NASDAQ · View IPO details →
Analyst price targets on KOD
Current price targets from 3 firms average $91.3, median $112, ranging from $36 to $126 — the average is 6% above the current $85.8. Each is tracked to its date and scored the same way a member's call is.
- H.C. Wainwright $99.9 → $126 by Oct 2027 Oct 12, 2026 via Investing.com · H.C. Wainwright's track record
- H.C. Wainwright $89.9 → $58 by Sep 2027 Sep 28, 2026 via Investing.com · H.C. Wainwright's track record
- Jefferies $89.9 → $112 by Sep 2027 Sep 28, 2026 via Investing.com · Jefferies's track record
- Goldman Sachs $89.9 → $36 by Sep 2027 Sep 28, 2026 via Investing.com · Goldman Sachs's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
Kodiak Sciences Inc net income history (FY2016–FY2025)
Net income
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Operating income | −$17.2M | −$25.5M | −$26.4M | −$49.2M | −$136.0M | −$267.1M | −$341.4M | −$277.3M | −$186.8M | −$234.4M |
| Net income | −$17.1M | −$27.9M | −$41.4M | −$47.4M | −$133.1M | −$267.0M | −$333.8M | −$260.5M | −$176.2M | −$230.0M |
| EPS (diluted) | −$2.38 | −$3.72 | −$2.77 | −$1.25 | −$2.91 | −$5.16 | −$6.39 | −$4.97 | −$3.35 | −$4.32 |
| Balance sheet | ||||||||||
| Cash and equivalents | $9.62M | $1.40M | $88.3M | $211.8M | $944.4M | $731.5M | $190.4M | $285.5M | $168.1M | $209.9M |
| Total assets | — | $3.24M | $92.2M | $358.9M | $1.07B | $904.2M | $666.6M | $479.4M | $335.6M | $351.5M |
| Total liabilities | — | $22.0M | $5.36M | $13.5M | $206.6M | $240.9M | $230.5M | $213.6M | $185.3M | $194.2M |
| Shareholders' equity | −$41.1M | −$68.7M | $86.8M | $345.4M | $860.8M | $663.3M | $436.2M | $265.8M | $150.3M | $157.4M |
| Cash flow | ||||||||||
| Operating cash flow | −$16.0M | −$17.7M | −$29.0M | −$39.1M | −$83.4M | −$182.3M | −$206.5M | −$154.2M | −$117.3M | −$136.0M |
| Capital expenditure | $771.0K | $209.0K | $78.0K | $437.0K | $3.81M | $17.0M | $37.0M | $41.4M | $375.0K | $506.0K |
| Free cash flow | −$16.8M | −$17.9M | −$29.1M | −$39.6M | −$87.2M | −$199.3M | −$243.5M | −$195.5M | −$117.7M | −$136.5M |
| Share buybacks | $4.00K | $0 | $0 | — | — | — | — | — | — | — |
Net income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$46.6M | −$46.2M | −$59.1M | −$55.5M | −$62.4M | −$57.5M | −$59.8M | −$66.8M |
| Net income | −$43.9M | −$44.1M | −$57.5M | −$54.3M | −$61.5M | −$56.7M | −$58.2M | −$65.6M |
| EPS (diluted) | −$0.84 | −$0.83 | −$1.09 | −$1.03 | −$1.16 | −$1.04 | −$0.94 | −$1.05 |
| Balance sheet | ||||||||
| Cash and equivalents | $197.9M | $168.1M | $138.9M | $104.2M | $72.0M | $209.9M | $169.5M | $125.9M |
| Total assets | $372.7M | $335.6M | $297.9M | $256.7M | $218.1M | $351.5M | $306.0M | $256.8M |
| Total liabilities | $187.3M | $185.3M | $189.1M | $186.4M | $194.4M | $194.2M | $193.9M | $195.7M |
| Shareholders' equity | $185.4M | $150.3M | $108.8M | $70.3M | $23.7M | $157.4M | $112.1M | $61.1M |
| Cash flow | ||||||||
| Operating cash flow | −$21.2M | −$30.1M | −$29.1M | −$34.7M | −$32.9M | −$39.4M | −$40.0M | −$46.2M |
| Capital expenditure | $180.0K | $124.0K | $270.0K | $133.0K | $60.0K | $43.0K | $942.0K | $352.0K |
| Free cash flow | −$21.3M | −$30.2M | −$29.3M | −$34.8M | −$32.9M | −$39.4M | −$41.0M | −$46.6M |
From Kodiak Sciences Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Kodiak Sciences Inc
- Headquarters
- Palo Alto, California From SEC filings, Oct 2026
Recent News (12)
-
How Investors May Respond To Kodiak Sciences Stock After Wet AMD Trial Success How Investors May Respond To Kodiak Sciences Stock After Wet AMD Trial Success Simply Wall Street
-
H.C. Wainwright raises Kodiak Sciences stock price target on trial data
H.C. Wainwright raises Kodiak Sciences stock price target on trial data
-
-
MDB, KOD, NVTS, BA, NVDA: 5 Trending Stocks Today - NVIDIA (NASDAQ:NVDA) MDB, KOD, NVTS, BA, NVDA: 5 Trending Stocks Today - NVIDIA (NASDAQ:NVDA) Benzinga
-
Jefferies cuts Kodiak Sciences stock price target on valuation review
Jefferies cuts Kodiak Sciences stock price target on valuation review
-
OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs TradingView
-
Stocks making the biggest moves midday: MongoDB, Boeing, Kodiak Sciences, Roblox, Nvidia & more Stocks making the biggest moves midday: MongoDB, Boeing, Kodiak Sciences, Roblox, Nvidia & more CNBC
-
-
Kodiak Sciences stock soars on positive AMD trial data
Kodiak Sciences stock soars on positive AMD trial data
-
Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration Kodiak Sciences to Host Webcast on Monday, September 28 at 8:30 AM Eastern Time PALO ALTO, Calif., Sept. 25, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused bio…
-
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results PALO ALTO, Calif., Aug. 13, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended June 30, 2026. "Kodiak…
-
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International